Celemics Inc is a Korea-based company mainly engaged in manufacturing products related to life science medicine. The Company mainly develops and sells target capture kit products. In addition, the Company is engaged in immune repertoire analysis solutions and next-generation sequencing solutions. The Company sells its products in domestic and overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
22/09/26	KRW 10,930.00	+0.64%	14,314
21/09/26	KRW 10,860.00	-3.89%	33,814
18/09/26	KRW 11,300.00	+0.62%	59,021
17/09/26	KRW 11,230.00	-1.66%	151,035
16/09/26	KRW 11,420.00	-5.39%	51,092

End-of-day quote Korea S.E.

More quotes

Annual profits - Rate of surprise

Company calendar

End-of-day quote Korea S.E. 22/09/2026			5-day change	1st Jan Change
10,930.00 ^KRW	+0.64%		-14.54%	+302.58%

24/06	Celemics, Inc. announced that it expects to receive KRW 9.9999956 billion in funding from Cnp Co., Ltd.	CI
29/05	Celemics, Inc. announced that it has received KRW 11.5999945 billion in funding	CI

Market Cap	122B 90.19M 78.83M 73.94M 67.71M 127M 8.62B 127M 887M 342M 4.4B 339M 331M 14.23B	P/E 2024	2.19x	P/E 2025	-5.49x
Enterprise Value	117B 86.11M 75.25M 70.59M 64.64M 121M 8.23B 121M 847M 327M 4.2B 323M 316M 13.58B	EV / Sales 2024	2.56x	EV / Sales 2025	2.88x
Free-Float	74.26%	Yield 2024 *	-	Yield 2025	-

24/06	Celemics, Inc. announced that it expects to receive KRW 9.9999956 billion in funding from Cnp Co., Ltd.	CI
29/05	Celemics, Inc. announced that it has received KRW 11.5999945 billion in funding	CI
30/04	Celemics, Inc. announced that it has received KRW 8.292707441 billion in funding	CI
28/04	Celemics, Inc. announced that it has received KRW 14.7 billion in funding	CI
31/03	Celemics, Inc. announced that it expects to receive KRW 11.5999945 billion in funding	CI
30/03	Celemics, Inc. announced that it expects to receive KRW 27 billion in funding	CI
13/03	Park Jong-gap completed the acquisition of an additional 5.27% stake in Celemics, Inc. from Kim Hyo-gi, Lee Yong-hoon.	CI
03/02	Celemics, Inc. announced that it expects to receive KRW 9.2927074 billion in funding	CI
03/02	Park Jong-gap agreed to acquire an additional 5.27% stake in Celemics, Inc. from Hyo-gi Kim, Yong-hoon Lee for KRW 2.6 billion.	CI
19/09/22	Celemics, Inc.(KOSDAQ:A331920) dropped from S&P Global BMI Index	CI
22/03/21	Celemics, Inc.(KOSDAQ:A331920) added to S&P Global BMI Index	CI
21/08/20	Celemics, Inc. has completed an IPO in the amount of KRW 26.4 billion.	CI
18/03/20	Celemics, Inc. has filed an IPO.	CI

1 day	+0.64%
1 week	-14.54%
Current month	-16.37%
1 month	+27.09%
3 months	-15.92%
6 months	+59.80%
Current year	+302.58%

Celemics, Inc. Stock

Stocks

A331920

KR7331920009

Biotechnology & Medical Research

Valuation: Celemics, Inc.

Chart: Celemics, Inc.

Latest news: Celemics, Inc.

Press Releases: Celemics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Celemics, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 week	10,140	12,270
1 month	8,270	15,000
Current year	2,580	19,840
1 year	2,535	19,840
3 years	2,535	19,840
5 years	2,535	20,900
10 years	2,535	39,400

Manager	Title	Age	Since
Yong-Hun Lee CEO	Chief Executive Officer	61	01/01/2017
Hyo-Gi Kim CEO	Chief Executive Officer	43	01/01/2013
Sang-Seok Lee PRN	Corporate Officer/Principal	45	01/01/2020

Director	Title	Age	Since
Hyo-Gi Kim BRD	Director/Board Member	43	01/01/2013
Yong-Hun Lee BRD	Director/Board Member	61	01/01/2017
Sang-Seok Lee BRD	Director/Board Member	45	01/01/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELEMICS, INC.	+0.64%	-14.54%	+249.76%	+137.87%	88.33M
LONZA GROUP AG	+2.55%	+5.35%	+3.61%	+32.02%	46.68B
IQVIA HOLDINGS INC.	+0.08%	+1.66%	+44.26%	+35.60%	44.42B
REVOLUTION MEDICINES, INC.	+0.05%	-5.97%	+342.95%	+532.74%	41.32B
BEONE MEDICINES AG	+0.66%	+4.03%	+10.07%	+96.02%	41.58B
CELLTRION, INC.	-1.60%	-0.17%	+9.73%	+43.63%	30.14B
MEDPACE HOLDINGS, INC.	+0.96%	+5.84%	+26.39%	+161.70%	17.42B
ASCENDIS PHARMA A/S	-0.01%	-10.32%	-	-	15.6B
EUROFINS SCIENTIFIC SE	+1.15%	+9.42%	+26.21%	+42.84%	15.54B
TEMPUS AI, INC.	-1.08%	+24.08%	-12.52%	-	14.08B
Average	+0.45%	+2.62%	+77.83%	+135.30%	26.69B
Weighted average by Cap.	+0.52%	+1.94%	+70.56%	+142.88%

	2024	2025
Net sales	6.72B 4.96M 4.33M 4.06M 3.72M 6.97M 474M 6.96M 48.76M 18.83M 242M 18.62M 18.21M 782M	5.77B 4.26M 3.72M 3.49M 3.2M 5.98M 407M 5.98M 41.86M 16.16M 208M 15.98M 15.63M 672M
Net income	12.27B 9.05M 7.91M 7.42M 6.8M 12.72M 865M 12.71M 89.02M 34.37M 442M 33.99M 33.24M 1.43B	-4.04B -2.98M -2.6M -2.44M -2.24M -4.19M -285M -4.18M -29.29M -11.31M -145M -11.19M -10.94M -470M
Net Debt	-9.55B -7.05M -6.16M -5.78M -5.29M -9.9M -673M -9.89M -69.29M -26.75M -344M -26.46M -25.88M -1.11B	-5.54B -4.09M -3.57M -3.35M -3.07M -5.75M -391M -5.74M -40.2M -15.52M -200M -15.35M -15.01M -645M